Type 1 diabetes (T1D) is now understood as a progressive autoimmune disease that develops in stages, even before symptoms appear. This staging framework helps identify people at risk and opens up opportunities for early intervention or monitoring. One of the earliest indicators of T1D development is the presence of T1D-specific islet autoantibodies (IAb), proteins produced by the immune system that signal an ongoing autoimmune attack on insulin-producing cells.
Here's a detailed explanation of the four stages — two pre-symptomatic and two symptomatic:
- Stage 1: Two or more IAbs are present, but blood glucose levels are still normal. No symptoms are present, and insulin production is still adequate.
5-year risk of symptoms: ~44% - Stage 2: IAbs persist and blood glucose levels become abnormal due to continued β cell loss.
5-year risk: ~75% - Stage 3: Clinical symptoms appear. Diagnosis is confirmed.
Early Stage 3 may include a temporary “honeymoon phase” with reduced insulin needs. - Stage 4: Established T1D with ongoing decline in β-cell function following diagnosis.
The presence of IAbs can be detected with a simple blood test, allowing for early identification of T1D - even before symptoms appear. If a person has two or more persistent IAbs, the likelihood of developing clinical T1D approaches 100% over time. This early detection opens opportunities for closer monitoring, participation in preventive clinical trials, and potential use of therapies aimed at delaying disease progression.
Are you interested in EARLY T1D DETECTION?
Whether you're an individual, a clinician, or a research team interested in early T1D detection and you are living or working in EUROPE, you are in the right place!
Find and connect with early-stage T1D screening and monitoring initiatives across Europe.
Already running an early T1D detection or monitoring initiative? List your center in the INNODIA Navigator.
Looking to integrate early T1D detection into your clinical practice? Discover how INNODIA can support you.